NAS:PRTA (Ireland) Also trade in: Germany UK

Prothena Corp PLC

$ 9.49 0.55 (6.15%)
Volume: 1,126,253 Avg Vol (1m): 293,016
Market Cap $: 378.32 Mil Enterprise Value $: -31,790,000.00
P/E (TTM): 0.00 P/B: 1.19
Earnings Power Value -293.78
Net Current Asset Value 6.72
Tangible Book 7.83
Projected FCF -9.81
Median P/S Value 7.98
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
78.39% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
PRTA: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 7.54, Med: 10000, Max: 10000
Current: 10000
7.54
10000
Equity-to-Asset 0.68
Equity-to-Asset ranked lower than
57.01% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
PRTA: 0.68
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.63, Med: 0.91, Max: 0.98
Current: 0.68
0.63
0.98
Debt-to-EBITDA -0.49
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
PRTA: -0.49
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -0.49, Med: -0.35, Max: -0.33
Current: -0.49
-0.49
-0.33
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -0.19
DISTRESS
GREY
SAFE
Beneish M-Score -7.77
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 13.18%

Profitability & Growth : 2/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -12802.74
Operating Margin ranked lower than
95.20% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
PRTA: -12802.74
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -15121.8, Med: -4974.3, Max: -13.07
Current: -12802.74
-15121.8
-13.07
Net Margin % -13978.88
Net Margin ranked lower than
95.58% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
PRTA: -13978.88
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -16297.91, Med: -5016.3, Max: -14.06
Current: -13978.88
-16297.91
-14.06
ROE % -36.71
ROE ranked lower than
53.99% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
PRTA: -36.71
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -68.99, Med: -39.67, Max: -3.09
Current: -36.71
-68.99
-3.09
ROA % -24.08
ROA ranked lower than
52.49% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
PRTA: -24.08
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -1640.13, Med: -31.67, Max: -2.94
Current: -24.08
-1640.13
-2.94
ROC (Joel Greenblatt) % -186.48
ROC (Joel Greenblatt) ranked higher than
57.92% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
PRTA: -186.48
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -2303.58, Med: -855.43, Max: -186.48
Current: -186.48
-2303.58
-186.48
3-Year Total Revenue Growth Rate -15.90
3-Year Revenue Growth Rate ranked lower than
73.73% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
PRTA: -23.2
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -33.7, Med: -24.2, Max: 289
Current: -23.2
-33.7
289
3-Year Total EBITDA Growth Rate -23.50
3-Year EBITDA Growth Rate ranked lower than
97.88% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
PRTA: -13.1
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -155.9, Med: -20.8, Max: 50.7
Current: -13.1
-155.9
50.7
3-Year EPS w/o NRI Growth Rate -13.90
3-Year EPS w/o NRI Growth Rate ranked lower than
97.90% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
PRTA: -13.9
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -141.2, Med: -21.15, Max: 47.9
Current: -13.9
-141.2
47.9

» PRTA's 30-Y Financials

Financials (Next Earnings Date: 2019-08-07)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:PRTA

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:DVAX NAS:TCRR NAS:PDLI SZSE:300705 NAS:PGNX NAS:KLDO SZSE:300404 NAS:PRQR NAS:ACHN NAS:ADVM NAS:FPRX NAS:SIGA NAS:CYCN NAS:TBIO SHSE:600556 XKRX:208340 OSTO:PROB SZSE:002872 NAS:SRNE TSXV:EMH
Traded in other countries 0PT.Germany 0Y3M.UK
Address Upper George's Street, Adelphi Plaza, Dún Laoghaire, Dublin, IRL, A96 T927
Prothena Corp PLC is a biotechnology company focuses on the discovery, development, and commercialization of novel protein immunotherapies for the treatment of diseases that involve protein misfolding and inflammatory cell adhesion disorders. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Ratios

Current vs industry vs history
PB Ratio 1.19
PB Ratio ranked higher than
80.98% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
PRTA: 1.19
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.84, Med: 3.36, Max: 6.28
Current: 1.19
0.84
6.28
PS Ratio 412.60
PS Ratio ranked lower than
94.49% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
PRTA: 412.6
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 8.28, Med: 347.06, Max: 1915
Current: 412.6
8.28
1915
EV-to-EBIT 0.30
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
PRTA: 0.3
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -348.9, Med: -9.85, Max: 0.9
Current: 0.3
-348.9
0.9
EV-to-EBITDA 0.30
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
PRTA: 0.3
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -103.1, Med: -9.4, Max: 4476
Current: 0.3
-103.1
4476
EV-to-Revenue -34.78
EV-to-Revenue ranked lower than
82.10% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
PRTA: -34.78
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -33, Med: 96, Max: 1555.4
Current: -34.78
-33
1555.4
Current Ratio 27.85
Current Ratio ranked higher than
77.84% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
PRTA: 27.85
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.01, Med: 19.34, Max: 72.16
Current: 27.85
0.01
72.16
Quick Ratio 27.85
Quick Ratio ranked higher than
78.40% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
PRTA: 27.85
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.01, Med: 19.34, Max: 72.16
Current: 27.85
0.01
72.16
Days Sales Outstanding 0.80
Days Sales Outstanding ranked higher than
94.61% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
PRTA: 0.8
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 0.76, Med: 37, Max: 115.61
Current: 0.8
0.76
115.61

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -7.60
3-Year Share Buyback Rate ranked higher than
53.33% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
PRTA: -7.6
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -23.6, Med: -15.7, Max: -7.6
Current: -7.6
-23.6
-7.6

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 1.21
Price-to-Tangible-Book ranked higher than
85.79% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
PRTA: 1.21
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1, Med: 3.45, Max: 5.99
Current: 1.21
1
5.99
Price-to-Median-PS-Value 1.19
Price-to-Median-PS-Value ranked lower than
93.51% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
PRTA: 1.19
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.03, Med: 0.94, Max: 5.52
Current: 1.19
0.03
5.52
Earnings Yield (Joel Greenblatt) % 339.43
Earnings Yield (Greenblatt) ranked lower than
96.48% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
PRTA: 339.43
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -3771.7, Med: -9.4, Max: 74709.2
Current: 339.43
-3771.7
74709.2

More Statistics

Revenue (TTM) (Mil) $ 0.91
EPS (TTM) $ -3.2
Beta 2.2
Volatility % 38.38
52-Week Range $ 8.63 - 15.91
Shares Outstanding (Mil) 39.86

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N